Mouse protein disrupts cancer-causing epigenetic changes in human colorectal cancer

"For solid tumors - the major killers in cancer - there is a tremendous unmet need to develop new approaches to therapeutically block DNA methylation abnormalities," says corresponding co-author Stephen Baylin, M.D., the Virginia and D.K. Ludwig Professor of Oncology and Medicine at Johns Hopkins and co-director of the Johns Hopkins Kimmel Cancer Center Genetics and Epigenetics Program.

Xiangqian Kong, Guangzhou Institute of Biomedicine and Health, Chinese Academy of SciencesThis is a novel approach to take the emerging need for epigenetic therapy in cancer forward in a very palpable way."

Source:

Johns Hopkins Medicine